Ipamorelin.

A plausible signal is not a proven result

Ipamorelin can trigger the release of growth hormone in the body. That does not establish improved sleep, recovery, body composition or injury healing. To answer those questions, trials would need defined products, suitable comparators, meaningful outcomes and adequate follow-up. See storage claims, product quality and travel for practical context. Explore how to read a result. Compare the distinct studies in CJC-1295 versus ipamorelin. For a different, non-peptide compound acting on the ghrelin receptor, see ibutamoren (MK-677).

For the bigger picture, follow the growth-hormone signal and its connection to muscle, fat and sleep.

For a related question, compare ipamorelin and MK-677: shared signals and different evidence.1

What did a human trial actually test?

A 2014 randomised, double-blind study investigated intravenous ipamorelin in adults after bowel surgery, not sleep, muscle gain or injury recovery. Of 117 people enrolled, 114 received study treatment. The main outcome was time until a solid meal could be tolerated. The ipamorelin group’s median time was shorter, but the difference from placebo was not statistically significant; the trial did not establish effectiveness for that outcome. This short hospital study cannot establish whether wellness use is beneficial or safe, including when the product is taken by another route.

In that published trial, the median time to tolerate a meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. The difference could reflect chance; a non-significant result also does not prove the treatments are identical.

A separate phase 2 postoperative study, NCT01280344, is listed on ClinicalTrials.gov as completed with 320 participants. When checked on 6 November 2026, its registry record had no results posted and was last updated in 2017. Registration and completion do not tell us whether it worked or what harms occurred, and absence of results in this registry does not prove they were never published elsewhere.346

What happened in the safety report?

Two participants who received intravenous ipamorelin died after complications following bowel surgery. The FDA briefing says it is unclear whether the study drug was involved. This does not prove ipamorelin caused the deaths or give a risk rate for other products or settings. It also cannot rule out harms from other routes or longer use.4

The same briefing reports serious adverse events in 10 of 56 people who received ipamorelin and 9 of 58 who received placebo. These included postoperative complications, and some people had more than one event. Because the study was small and the participants were having surgery, it cannot show whether ipamorelin caused those events or reliably compare uncommon harms.4

The FDA briefing also reported low blood potassium in 12.5% of the ipamorelin group versus 3.4% of the placebo group, and high blood sugar at discharge in 14.3% versus 8.6%. These observations in a small intravenous postoperative study raised safety concerns; they do not establish causation or predict rates with other products or routes. People with diabetes, glucose concerns or electrolyte problems should discuss any product with a clinician.4

Route and formulation change the question

FDA distinguishes available information by route and formulation. A small study using an intravenous preparation cannot be used to assure the safety of a subcutaneous product, nasal product or online vial. Aggregation, impurities and unnatural amino acids can complicate characterisation.41

In its 2024 assessment, FDA said it had not identified safety or effectiveness data for the proposed under-the-skin route in the uses it evaluated. Weighing the evidence and safety and product-characterisation concerns, the agency proposed against adding ipamorelin free base or acetate to the section 503A bulk-substances list. That was an evaluation and proposal, not a final decision about every product.4

FDA’s current compounding-safety page lists ipamorelin acetate in its 503B category 2 table and cites possible immunogenicity from aggregation or peptide-related impurities, plus the intravenous serious-event report. That listing describes FDA’s safety concern; it does not make every online product equivalent or establish a risk rate for subcutaneous use.5

What to do with the safety signal

A reported serious event does not prove that ipamorelin caused it or establish how often it happens. It does show why confident ‘safe’ claims exceed the evidence. This page does not give dosing, stacking or injection instructions.12

Development & regulatory context

These selected records are not a complete global legal-status list. Approval depends on the product, use, population and country; check each record’s date.